fbpx
  • Home
  • Study Details
Open

XTRA Study

We are learning about the safety of combining a cell therapy (HXTC therapy) with regular doses of a drug called Vorinostat (VOR) as a possible approach for improving the strength of your immune system against HIV. In this study, we will collect your blood, remove the cells in your immune system that fight infection (T cells), and expose them to HIV proteins so that they will recognize the HIV virus again. These re-educated T cells are called HXTCs (HIV-specific T cells). In this study we will use HXTC therapy (putting your re-educated T cells back into your body to get your immune system to respond better against HIV) along with the drug VOR, which has been shown to stimulate your resting CD4 cells to become active and release the HIV virus.

Age & Gender

  • 18 years ~ 64 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)
  • Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

Clinic visits with 2 blood procedures

Incentives

up to $3350 for completion of all study visits and procedures, Travel reimbursement may be available for participants who travel more than 50 miles one-way to the study visits.

In-person visits : 24
Total length of participation : up to 13 months (1 year and 1 month)

Looking for Specific Volunteers

Able to participate:

  • Male and female people living with HIV
  • On antiretroviral therapy (ART) and suppressed for at least 2 years
  • CD4 count greater than 350 cells/mm3
  • Have ability to have a driver present to transport home after some visits
  • Able and willing to continue ART throughout the study

Not eligible if:

  • Problems with having your blood drawn
  • You have a known cardiovascular risk
  • Active syphilis, Hepatitis B or C infection
  • You are pregnant or breastfeeding or planning to get pregnant or father a child
  • You are receiving chemotherapy or radiation therapy for any active cancer

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

David Margolis
Medicine-Infectious Diseases

Study Type

Clinical or Medical
Interventional

Study Topics

HIV/AIDS

IRB Number

17-0468

ClinicalTrials.gov

NCT03212989

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.